Literature DB >> 22459769

Lung resection in hematologic patients with pulmonary invasive fungal disease.

Christian A Nebiker1, Didier Lardinois2, Lilian Junker3, Franco Gambazzi2, Peter Matt4, James M Habicht4, Joerg Halter5, Dominik Heim5, Martin Stern5, Andreas S Buser5, Jakob Passweg5, Daiana Stolz3, Ursula M Flückiger6, Maja Weisser6, Manuel Battegay6, Lukas Bubendorf7, Alois Gratwohl5, Michael Tamm3.   

Abstract

BACKGROUND: Pulmonary invasive fungal disease is a frequent complication in patients with hematologic malignancies. Surgical resection in addition to antifungal therapy is an option for selected cases but often feared because of immunosuppression.
METHODS: We analyzed the outcome of 71 patients undergoing lung resection for pulmonary invasive fungal disease. Most patients had leukemia, 44 underwent high-dose chemotherapy, and 18 underwent stem cell transplantation.
RESULTS: On the day of surgery, 44 patients were neutropenic, and 41 had a platelet count < 50 × 109/L. Forty-five nonanatomic (atypical) resections and 26 lobectomies were performed. Fungal infection was histologically proven in 53 patients. Reoperation was needed in four patients (bronchial stump dehiscence, persistent air leak, chylothorax, and seroma). Minor complications at the site of surgery occurred in 14 patients. In only two, there was an uncontrolled disseminated fungal infection. Overall, mortality at 30 days was 7% (five of 71). Long-term survival was mainly influenced by the underlying hematologic disease.
CONCLUSIONS: Lung resection is a therapeutic option for hematologic patients with pulmonary fungal infection. Despite immunosuppression, the perioperative morbidity and mortality is acceptable, and, therefore, the prognosis is not determined by the surgical intervention.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22459769     DOI: 10.1378/chest.11-1964

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  7 in total

1.  Survival following lung resection in immunocompromised patients with pulmonary invasive fungal infection.

Authors:  Geena X Wu; Marine Khojabekyan; Jami Wang; Bernard R Tegtmeier; Margaret R O'Donnell; Jae Y Kim; Frederic W Grannis; Dan J Raz
Journal:  Eur J Cardiothorac Surg       Date:  2015-03-01       Impact factor: 4.191

2.  Treatment options in Invasive Aspergillosis.

Authors:  Anil A Panackal; John E Bennett; Peter R Williamson
Journal:  Curr Treat Options Infect Dis       Date:  2014-09

3.  Surgery for localized pulmonary mycotic infections in patients with hematopoietic disorder.

Authors:  Youngkyu Moon; Jae Kil Park; Sook Whan Sung
Journal:  J Cardiothorac Surg       Date:  2015-06-30       Impact factor: 1.637

4.  Surgery for Pulmonary Fungal Infections Complicating Hematological Malignancies.

Authors:  Takashi Yamamichi; Hirotoshi Horio; Ayaka Asakawa; Masayuki Okui; Masahiko Harada
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2018-10-05

5.  Surgical management of invasive fungal infections in adult leukemia patients: experience from a large tertiary center in Southeast-Asia.

Authors:  Bryan M H Keng; Zhi Xuan Ng; Yan Chin Tan; Thuan Tong Tan; Gee Chuan Wong; Chandramouli Nagarajan
Journal:  Blood Sci       Date:  2019-08-01

6.  Aspergillus-PCR in bronchoalveolar lavage for detection of invasive pulmonary aspergillosis in immunocompromised patients.

Authors:  Michael Buess; Gieri Cathomas; Jörg Halter; Lilian Junker; Peter Grendelmeier; Michael Tamm; Daiana Stolz
Journal:  BMC Infect Dis       Date:  2012-10-02       Impact factor: 3.090

7.  Lung histology predicts outcome of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.

Authors:  Andreas Holbro; Thomas Lehmann; Sabine Girsberger; Martin Stern; Franco Gambazzi; Didier Lardinois; Dominik Heim; Jakob R Passweg; André Tichelli; Lukas Bubendorf; Spasenija Savic; Katrin Hostettler; Peter Grendelmeier; Joerg P Halter; Michael Tamm
Journal:  Biol Blood Marrow Transplant       Date:  2013-04-02       Impact factor: 5.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.